Zai Lab under pressure over clinical results and rival drugs
Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products Key Takeaways: The survival benefits for…
Cancer drug maker Genfleet joins Hong Kong IPO influx
The biotech can boast a long list of big-name backers and has brought a promising drug to the market with its partner Innovent, but its cash reserves are dwindling Key…
Drug Startups Eye Quicker Profits Under China’s New Fast-Track Approvals
Key changes designed to bring cutting-edge drugs more quickly to market have yet to ignite significant rally for money-losing startups Key takeaways: New fast-track approval system could bring cutting-edge drugs…
RELATED ARTICLES
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK -
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Akeso shares take a hit despite surging sales of cancer drugs
9926.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
Hengrui Pharma targets obesity drug launch after test success
1278.HK 600276.SHG
-
Investors cheer Akeso’s revenue milestone, even as it returns to the red
9926.HK
